No. of patients with available ESTA result | 51 | |||
ESTA results, n (%) | CCR5-tropic | 31 (61%) | ||
 |  | Dual/Mixed-tropic | 12 (23%) | |
 |  | CXCR4-tropic | 1 (2%) | |
 |  | Not Reportable | 7 (14%) | |
Descriptive | total | CCR5-tropic | Dual/Mixed/CXCR4-tropic | |
Female gender, n (%) | 16 (31%) | 12 (39%) | 4 (31%) | |
Mean age (SD) | 45 (9) | 46 (8) | 40 (12) | |
Median time from HIV-1 diagnosis, years (IQR) | 17 (14-19) | 16 (13-18) | 18 (17-22) | |
Italian nationality, n (%) | 48 (94%) | 29 (93%) | 12 (92%) | |
Risk Factor, n (%) | Heterosexual | 15 (29%) | 11 (35%) | 3 (23%) |
 | Homosexual/Bisexual | 17 (33%) | 11 (35%) | 4 (31%) |
 | IDU | 14 (27%) | 7 (23%) | 3 (23%) |
 | Other/Unknown | 5 (10%) | 2 (6%) | 3 (23%) |
CDC stage, n (%) | A | 16 (32%) | 11 (35%) | 3 (25%) |
 | B | 10 (20%) | 9 (29%) | 1 (8%) |
 | C | 24 (48%) | 11 (35%) | 8 (67%) |
History of mono-dual NRTI therapy, n (%) | 37 (72%) | 24 (77%) | 10 (77%) | |
Median duration of ART exposure, years (IQR) | 14 (11-16) | 13 (11-16) | 13 (11-15) | |
No. of drug switches (any change or interruption) experienced (IQR) | 13 (9-16) | 13 (9-15) | 11 (7-15) | |
Patients previously exposed to drug class, n (%) | NRTI | 50 (98%) | 31 (100%) | 13 (100%) |
 | NNRTI | 44 (86%) | 29 (93%) | 10 (77%) |
 | Unboosted PI | 49 (96%) | 30 (97%) | 13 (100%) |
 | Boosted PI | 35 (69%) | 22 (71%) | 8 (61%) |
CD4 count, median cells/mm3 (IQR) | 334 (182-535) | 387 (214-464) | 211 (198-518) | |
HIV-1 RNA load, median log10 cp/ml (IQR) | 3.66 (2.55-4.30) | 3.9 (3.6-4.1) | 4.2 (4.0-4.8) | |
CD4 count at nadir, median cells/mm3 (IQR) | 64 (18-191) | 138 (31-200) | 14 (6-41) | |
HIV-1 RNA load at zenith, median Log10 cp/ml (IQR) | 5.3 (4.6-5.7) | 5.5 (4.8-5.7) | 5.4 (4.5-5.6) |